Patent · US Active

Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide

US8299076B2 · kind B2 · utility

0Cited by

27References

24Claims

0Family size

Assignees

Array BioPharma, Inc. · US
ASTRAZENECA AB · SE

Inventors

Allison L. Marlow · Boulder, US
Eli M. Wallace · Richardson, US
Jeongbeob Seo · Boulder, US
Joseph P. Lyssikatos · South San Francisco, US
Hong Yang · Foster City, US
Jim Blake · Longmont, US
Richard Anthony Storey · Ashford, GB
Rebecca Jane Booth · Macclesfield, GB
John David Pittam · Macclesfield, GB
John Leonard · Grafton, GB
Mark Richard Fielding · Grafton, GB

Key dates

Filing date	May 17, 2006
Grant date	Oct 30, 2012
Priority date	—
Expiry date	Sep 29, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D213/85
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are crystalline forms of 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.